Quotient Limited Announces Manuel Mendez as Chief Executive Officer
JERSEY, Channel Islands, 23 February 2021 (GLOBE NEWSWIRE) --Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that Manuel Mendez has been appointed as Chief Executive Officer of the Company and will begin serving in that role on April 1st, 2021.…
Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Quotient Limited Reports Third Quarter Fiscal 2021 Results and Business Update
• MosaiQ COVID-19 semi-quantitative antibody test CE marked
• Expanded MosaiQ IH microarray EU launch planned for fourth quarter CY2021
• Sales of Alba by Quotient reagents exceed guidance
• Strong cash position in place to carry us into commercialization
• Expanded MosaiQ IH microarray EU launch planned for fourth quarter CY2021
• Sales of Alba by Quotient reagents exceed guidance
• Strong cash position in place to carry us into commercialization
Quotient Limited to Report Third Quarter 2021 Financial Results and Host Conference Call
JERSEY, Channel Islands, Jan. 19, 2021 (GLOBE NEWSWIRE) – Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2020 will be released before market open on Monday, February 1, 2021.
Quotient Limited Announces Departure of Chief Operating Officer
JERSEY, Channel Islands, 22 December 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that on December 21, 2020, Ed Farrell delivered a notice of resignation from his position as the Company's Chief Operating Officer…
Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market
Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data
JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed…
Quotient Limited to Participate in Two Upcoming Conferences
JERSEY, Channel Islands, November 9, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that the Company will participate in two upcoming virtual investor conferences.
Quotient Limited Reports Second Quarter Fiscal 2021 Results and Business Update
• FDA Emergency Use Authorization for the MosaiQ COVID-19 antibody test received
• FDA 510(k) clearance for Initial MosaiQ SDS microarray and MosaiQ instrument expected before the end of CY2020
• European field trial for Expanded MosaiQ IH microarray progressing; on track for CE Mark…
• FDA 510(k) clearance for Initial MosaiQ SDS microarray and MosaiQ instrument expected before the end of CY2020
• European field trial for Expanded MosaiQ IH microarray progressing; on track for CE Mark…